TransMedics, Inc. Raises $36 Million for Organ Transplant Tech

Published: Nov 26, 2012

TransMedics Inc., an Andover medical device company that develops organ transplant technologies, has raised $36 million in equity, according to federal filings. The funding, which comes from 15 investors, comes a little more than a year after the company’s last fundraise of $6 million from nine investors, which was itself a little more than a year after the previous investment of $35 million from 26 investors. The company has now raised at least $166 million since it was founded in 1998 by CEO and President Waleed Hassanein. The filing with the U.S. Securities and Exchange Commission includes several company directors on its list of related persons: David Abrams and Travis Rhodes of Abrams Capital; Kenneth Bate, director at BioMarin Pharmaceutical, AVEO Pharmaceuticals and non-executive chairman at Cubist Pharmaceuticals; Joe Lacob, who has been a partner at venture firm Kleiner Perkins Caufield & Byers; and Earl M. Collier, CEO at Arsenal Medical and 480 Biomedical Inc. and senior advisor at Polaris Ventures. Previous backers of the company have included 3i Group, Alta Partners, CB Health Ventures, Flagship Ventures, JP Morgan, Posco BioVentures, Sagamore Bioventures, Sherbrooke Capital, Tudor Investment Corp. and VantagePoint Venture Partners.

Back to news